This invention relates to novel
anthraquinone compounds useful in the treatment of allergic, inflammatory conditions,
antioxidant, tumor condition,
stem cell application,
tissue engineering, applied in treating age-associate
tissue degeneration, reverse organ failure in chronic high-turnover
disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized
anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted
anthraquinone compounds according to formula I: wherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain
alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of
halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, and —OCH2CH2CH3; and wherein R6 is selected from the group consisting of a straight or branched chain
alkyl group having 1 to 4 carbons,
halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2Br, —CH2Cl, —CH2OH, —C(CH3)3, —(CH2)20H, —(CH2)3OH, —(CH2)4OH, —CH2NH2, —(CH2)2NH2, —(CH2)3NH2, —(CH2)4NH2, —(CH2)5NH2, —CH2N(CH3)2, —(CH2)2N(CH3)2, —(CH2)2NH(CH2)2OH, —(CH2)3NH(CH2)2OH, —(CH2)2NHCH2OH, —(CH2)3NHCH2OH, —CH2CH(CH3)2, —CHCl2, —CH(CH3)Cl, —(CH2)2Cl, —(CH2)3Cl, —(CH2)3Br, —(CH2)4Br, and —(CH2)4Cl. Chart 1. Activation of hTERT
promoter-driven SEAP expression by c-Myc. About 1×107 hTERT-BJ1 cells were transfected with 13.5 μg each of
plasmid pSEAP or pPhTERT-SEAP and of
plasmid pMT2T or pMT2T-cMyc by
electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×105 / mL, and the SEAP activity after 24 h at 37 □. The
transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of
plasmid pCMVβ. The values were determined from three experiments. P<0.05 is presented by an
asterisk.